COMP <GO>
INGN vs UNH // REVENUE GROWTH (YOY)
Inogen Inc (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: INGN 4
— UNH 8
▲ REVENUE GROWTH (YOY) LEADER: INGN
LAST: $6.87 (+0.15%) • MKT CAP: $182.3M
revenue-growth
5.90%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INGN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INGN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.20% | 88.31% | -36.11 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.00% | 12.38% | -39.38 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.13% | 6.25% | -13.38 | UNH | /fcf-yield <GO> |
| Operating Margin | -10.20% | 5.32% | -15.52 | UNH | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 3.53% | +4.17 | INGN | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.90% | 3.33% | +2.57 | INGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.46 | 3.09 | -1.63 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.6 | 55.1 | +2.50 | INGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 7.9x | 17.7x | -9.84 | INGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $182.3M | $359.43B | -$359.25B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INGN REV | UNH REV | INGN GROSS % | UNH GROSS % | INGN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $295.3M | $447.57B | 52.2% | 88.7% | -$13.7M | $16.07B |
| FY 2024 | $278.8M | $400.28B | 55.5% | 88.3% | $2.6M | $20.70B |
| FY 2023 | $251.6M | $371.62B | — | 89.6% | -$3.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INGN // BETA —
UNH // BETA 0.33